» Articles » PMID: 21791594

In Vivo Ocular Fluorophotometry: Delivery of Fluoresceinated Dextrans Via Transscleral Diffusion in Rabbits

Overview
Specialty Ophthalmology
Date 2011 Jul 28
PMID 21791594
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the transscleral delivery of fluoresceinated dextrans (FITC-D) with molecular mass up to 70 kDa to the rabbit posterior segment using sub-Tenon injections.

Methods: Eighteen NZW rabbits received a unilateral 200-μL injection of 2 mg/mL sodium fluorescein (NaF), 25 mg/mL 40-kDa FITC-D, or 25 mg/mL 70-kDa FITC-D, with (n = 9) or without (n = 9) immediate euthanatization. In live animals, fluorescence was measured in the retina/choroid and mid-vitreous by fluorophotometry, immediately after injection and after 4, 24, 48, and 72 hours. Euthanatized animals were examined hourly through 5 or 6 hours.

Results: In live animals, the average peak NaF concentration in the retina/choroid was 310.2 ng/mL, measured 3 hours after injection. Average 40- and 70-kDa FITC-D concentrations in the retina/choroid peaked at 5409.6 and 2375.6 ng/mL, respectively, 24 hours after injection. Fluorescence returned to baseline levels 6 hours after NaF injection, and 48 and 72 hours after 40- and 70-kDa FITC-D injections, respectively. Rabbits that received NaF followed by euthanatization exhibited a continuous increase in retina/choroid and mid-vitreous fluorescence, beginning 1 hour after injection, whereas FITC-D-injected eyes did not show elevated retina/choroid or mid-vitreous fluorescence through 6 hours.

Conclusions: FITC-D weighing up to 70-kDa, as well as NaF, reached the posterior retina/choroid after sub-Tenon injections in live rabbits. NaF and 40-kDa FITC-D reached higher peak concentrations and were cleared from the eye more rapidly than was 70-kDa FITC-D. There was minimal penetration of NaF and FITC-D into the mid-vitreous in the in vivo experiments.

Citing Articles

Assessment of Inner Blood-Retinal Barrier: Animal Models and Methods.

Bora K, Kushwah N, Maurya M, Pavlovich M, Wang Z, Chen J Cells. 2023; 12(20).

PMID: 37887287 PMC: 10605292. DOI: 10.3390/cells12202443.


Fluorophotometric Determination of Riboflavin Concentrations in a Human Artificial Anterior Chamber Model.

Iselin K, Thiel M, Bachmann L, Baenninger P, Kaufmann C Transl Vis Sci Technol. 2019; 8(6):7.

PMID: 31737431 PMC: 6855370. DOI: 10.1167/tvst.8.6.7.


Ocular Biodistribution Studies using Molecular Imaging.

Castro-Balado A, Mondelo-Garcia C, Gonzalez-Barcia M, Zarra-Ferro I, Otero-Espinar F, Ruibal-Morell A Pharmaceutics. 2019; 11(5).

PMID: 31100961 PMC: 6572242. DOI: 10.3390/pharmaceutics11050237.


Ocular Drug Distribution and Safety of a Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in Rabbit.

Papangkorn K, Higuchi J, Brar B, Higuchi W J Ocul Pharmacol Ther. 2018; 34(4):325-334.

PMID: 29432054 PMC: 5952332. DOI: 10.1089/jop.2017.0093.


Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in the Treatment of Experimental Uveitis Rabbit.

Papangkorn K, Prendergast E, Higuchi J, Brar B, Higuchi W J Ocul Pharmacol Ther. 2017; 33(10):753-762.

PMID: 29022761 PMC: 5733740. DOI: 10.1089/jop.2017.0053.


References
1.
Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

2.
Ghate D, Brooks W, McCarey B, Edelhauser H . Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci. 2007; 48(5):2230-7. DOI: 10.1167/iovs.06-0954. View

3.
Alm A, Nilsson S . Uveoscleral outflow--a review. Exp Eye Res. 2009; 88(4):760-8. DOI: 10.1016/j.exer.2008.12.012. View

4.
Edelhauser H, Rowe-Rendleman C, Robinson M, Dawson D, Chader G, Grossniklaus H . Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010; 51(11):5403-20. PMC: 3061492. DOI: 10.1167/iovs.10-5392. View

5.
Klein K, Walsh M, Hassan T, Halperin L, Castellarin A, Roth D . Endophthalmitis after anti-VEGF injections. Ophthalmology. 2009; 116(6):1225.e1. DOI: 10.1016/j.ophtha.2009.02.031. View